Centrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation

Fundamental and Clinical Pharmacology

Volumn 18, Issue 1, 2004, Pages 71-77

  Cavun, Sinan ^a   Savci, Vahide ^a   Ulus, Ismail H ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

CDP choline; Choline; Cytidine; Nicotinic receptor; Precursor; Vasopressin

Indexed keywords

ATROPINE; CHOLINE; CITICOLINE; CYTIDINE; HEMICHOLINIUM 3; MECAMYLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; VASOPRESSIN;

ANIMAL EXPERIMENT; ARTICLE; CHOLINE UPTAKE; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG RESPONSE; INHIBITION KINETICS; INJECTION; MALE; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; ATROPINE; CHOLINERGIC AGENTS; CYTIDINE; CYTIDINE DIPHOSPHATE CHOLINE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HEMICHOLINIUM 3; INJECTIONS, INTRAVENTRICULAR; MALE; MECAMYLAMINE; MUSCARINIC ANTAGONISTS; NICOTINIC ANTAGONISTS; NOOTROPIC AGENTS; PARASYMPATHETIC NERVOUS SYSTEM; RATS; RATS, WISTAR; RECEPTORS, PRESYNAPTIC; STIMULATION, CHEMICAL; SYNAPSES; VASOPRESSINS;

EID: 1042288132     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0767-3981.2003.00213.x     Document Type: Article

References (33)

1. Weiss G.B. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. (1995) 56 637-660.
2. Amenta F., Parnetti L., Gallai V., Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech. Ageing Dev. (2001) 16 2025-2040.
3. Cacabelos R., Alvarez X.A., Franco-Maside A., Fernandez-Novoa L., Caamano J. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multiinfarct dementia. Ann. N. Y. Acad. Sci. (1994) 16 211-218.
4. Cacabelos R., Alvarez X.A., Fernandez-Novoa L., Lombardi V.R. A pharmacogenomic approach to Alzheimer's disease. Acta. Neurol. Scand. Suppl. (2000) 176 12-19.
5. D'Orlando K.J., Sandage B.W. Jr. Citicoline (CDP-choline): mechanism of action and effects in ischemic brain injury. Neurol. Res. (1995) 17 281-284.
6. Wurtman R.J. Neuronal death mechanisms in cerebral ischemia: laboratory at the clinic. Rev. Neurol. (1999) 29 524-526.
7. Lopez G., Coviella I., Agut J., Savci V., Ortiz J.A., Wurtman R.J. Evidence that 5′-cytidinediphosphocholine can affect brain composition by increasing choline and cytidine plasma levels. J. Neurochem. (1995) 65 889-894.
8. Wurtman R.J., Regan M., Ulus I.H., Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem. Pharmacol. (2000) 60 989-992.
9. Lopez G., Coviella I., Agut J., Von Borstel R., Wurtman R.J. Metabolism of cytidine (5′)-diphosphocholine (CDP-choline) following oral and intravenous administration to the human and the rat. Neurochem. Int. (1987) 11 293-297.
10. Savci V., Cavun S., Goktalay G., Ulus I.H. Cardiovascular effects of intracerebroventricularly injected CDP-choline in normotensive and hypotensive animals: the involvement of cholinergic system. Naunyn-Schmiedeberg's Arch. Pharmacol. (2002) 365 388-398.
11. Dixon C.E., Ma X., Marion D.W. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J. Neurotrauma. (1997) 14 161-169.
12. Armstrong D.M. Cholinergic innervation of vasopressin containing neurons in the supraoptic nucleus of the rat, in: Shirer R.B. (Ed.), Vasopressin, Raven Press, New York, USA, 1985, pp. 353-360.
13. Mason W.T., Ho Y.W., Eckenstein F., Hatton G.I. Mapping of cholinergic neurons associated with rat supraoptic nucleus: combined immunocytochemical and histochemical identification. Brain Res. Bull. (1983) 11 617-626.
14. Mason W.T. Staining of the magnocellular nuclei of the rat hypothalamus by a monoclonal antibody directed against the α-subunit of the nicotinic cholinergic receptor. Neurosci. Lett. (1985) 59 89-95.
15. Michels K.M., Meeker R.B., Hayward J.N. Differential distribution of muscarinic and putative nicotinic receptors within the hypothalamo- neurohypophysial system of the rat. Neuroendocrinology (1986) 44 498-507.
16. Gregg C.M. Actions of acetylcholine on the supraoptic hypothalamo-neurohypophysial system, in: Shirer R.E. (Ed.), Vasopressin, Raven Press, New York, USA, 1985, pp. 407-415.
17. Iitake K., Share L., Ouchi Y., Crofton J.T., Brooks D.P. Central cholinergic control of vasopressin release in conscious rats. Am. J. Physiol. (1989) 251 E146-E151.
18. Ota M., Crofton J.T., Toba K., Share L. Effect on vasopressin release of microinjection of cholinergic agonists into the rat supraoptic nucleus. Proc. Soc. Exp. Biol. Med. (1992) 201 208-214.
19. Shen E., Sun X. Endogenous acetylcholine-induced Fos expression in magnocellular secretory neurons in the supra-optic nucleus of the rat hypothalamus. Neurosci. Lett. (1995) 195 191-194.
20. Bisset G.W., Chowdrey H.S. A cholinergic link in the reflex release of vasopressin by hypotension in the rat. J. Physiol. (London) (1984) 354 523-545.
21. Sladek C.D., Armstrong W.E. Neural pathways subserving osmotic control of vasopressin release, in: Schrier R.B. (Ed.), Vasopressin, Raven Press, New York, USA, 1985, pp. 435-440.
22. Savci V., Goktalay G., Ulus I.H. Intracerebroventricular choline increases plasma vasopressin and augments vasopressin response to osmotic stimulation and haemorrhage. Brain Res. (2002) 942 58-70.
23. Savci V., Gurun M.S., Ulus I.H., Kiran B.K. Intracerebroventricular injection of choline increases plasma oxytocin levels in conscious rats. Brain Res. (1996) 709 97-102.
24. Savci V., Gurun M.S., Ulus I.H., Kiran B.K. Effects of intracerebroventricularly injected choline on plasma ACTH and -endorphine. Eur. J. Pharmacol. (1996) 309 275-280.
25. Ulus I.H., Arslan B.Y., Savci V., Kiran B.K. Restoration of blood pressure by choline treatment in rats made hypotensive by haemorrhage. Br. J. Pharmacol. (1995) 116 1911-1917.
26. Arslan B.Y., Ulus I.H., Savci V., Kiran B.K. Effects of intracerebroventricular injected choline on cardiovascular functions and sympathoadrenal activity. J. Cardiovasc. Pharmacol. (1991) 17 814-821.
27. Shioda S., Nakajo S., Hirabayashi T. et al. Neuronal nicotinic acetylcholine receptor in the hypothalamus: morphological diversity and neuroendocrine regulations. Mol. Brain Res. (1997) 47 45-54.
28. Li D.P., Pan H.L. Potentiation of glutamatergic synaptic input to supraoptic neurons by presynaptic nicotinic receptors. Am. J. Physiol. (2001) 281 1105-1113.
29. Rao T.S., Correa L.D., Lloyd G.K. Effects of lobeline and dimethylphenylpiperazinium iodid (DMPP) on N-methyl-D-aspartate (NMDA)-evoked acetylcholine release in vitro: evidence for a lack of involvement of classical neuronal nicotinic acetylcholine receptors. Neuropharmacology (1996) 36 39-50.
30. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of 7 nicotinic acetylcholine receptors in rat brain neurons. Eur. J. Neurosci. (1997) 9 2734-2742.
31. Mike A., Castro N.G., Albuquerque E.X. Choline and acetylcholine have similar kinetic properties of activation and desensitization on the 7 nicotinic receptors in rat hippocampal neurons. Brain Res. (2000) 882 155-168.
32. Alescio-Lautier B., Soumireu-Mourat B. Effects of peripherally administered arginine-vasopressin on learning, retention and forgetting in mice. Behav. Brain Res. (1990) 41 117-128.
33. Buijs R.M. Vasopressin and oxytocin - their role in neuro-transmission. Pharmac. Ther. (1983) 22 127-141.